{"page_content": "34      KODIAK 2021 ESG REPORT BACK TO CONTENTS >>SASB SUSTAINABILITY ACCOUNTING STANDARDS 2018\nTopic SASB Code Accounting or Activity Metric Response, Cross-reference, or Omission Source(s)\nAffordability  \n& PricingHC-BP-240b.1Number of settlements of Abbreviated New \nDrug Application (ANDA) litigation that \ninvolved payments and/ or provisions to delay \nbringing an authorized generic product to \nmarket for a defined time periodNA \n \nNone to disclose as of December 2021 \nbecause Kodiak has not yet started \ncommercial production and thus generic \nproduct production isn't possible at this timeN/A\nHC-BP-240b.2Percentage change in: (1) average list price \nand (2) average net price across U.S. product \nportfolio compared to previous yearNA \n \nNo percent change in list price to disclose as \nof December 2021 because Kodiak is not yet \nin commercial productionN/A\nHC-BP-240b.3Percentage change in: (1) list price and (2) \nnet price of product with largest increase \ncompared to previous yearNA \n \nNo percent change in list price to disclose as \nof December 2021 because Kodiak is not yet \nin commercial productionN/AKODIAK 2021 SASB INDEX", "metadata": {"source": "NASDAQ_KOD_2021.pdf", "page": 33, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}